Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.

Masatoshi IshigamiKazuhiko HayashiTakashi HondaTeiji KuzuyaYoji IshizuTetsuya IshikawaIsao NakanoFumihiro UranoTakashi KumadaKentaro YoshiokaHidemi GotoYoshiki Hirooka

Published in: Journal of gastroenterology and hepatology (2018)

Although the antiviral effect was slightly lower in patients with severe fibrosis compared with those without, treatment with daclatasvir and asunaprevir is basically an effective and well-tolerable treatment in these populations.

Keyphrases

hepatitis c virus
liver fibrosis
early onset
machine learning
smoking cessation